TAK 071

Drug Profile

TAK 071

Alternative Names: TAK-071

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antidementias; Nootropics
  • Mechanism of Action Muscarinic M1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 16 Jul 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2017)
  • 01 Dec 2016 Takeda initiates enrolment in a phase Ib pharmacodynamics trial in Healthy volunteers in USA (PO) (NCT02918266)
  • 27 Sep 2016 Takeda plans a phase Ib pharmacodynamics trial in Healthy volunteers in USA (PO) (NCT02918266)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top